Home Newsfeeds RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target

RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target

RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.

byBenzinga Newsdesk

March 15, 2023

1 minute read

RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.

Freight Technologies Shoot Up After Chardan Capital’s Bullish Rating

By Shivani Kumaresan

November 14, 2:31 PM

Chardan Capital analyst Brian Dobson initiated coverage on Freight Technologies (NASDAQ:FRGT) with a Buy rating and a price target of $2.25. The…

FRGT

Cincinnati Financial Q2 EPS $0.65 Misses $1.06 Estimate

By Bill Haddad

July 27, 4:38 PM

Cincinnati Financial (NASDAQ:CINF) reported quarterly earnings of $0.65 per share which missed the analyst consensus estimate of $1.06 by 38.68 percent. This is a 63.69 percent decrease over earnings of $1.79 per share

CINF

Morgan Stanley Maintains Equal-Weight on Wynn Resorts, Raises Price Target to $95

By Benzinga Newsdesk

February 1, 11:35 AM

Morgan Stanley analyst Stephen Grambling maintains Wynn Resorts (NASDAQ:WYNN) with a Equal-Weight and raises the price target from $83 to $95.

WYNN

Binance Says Worldwide Inflation Is Driving Crypto User Growth

By Samyuktha Sriram

August 11, 2:42 AM

A senior executive at cryptocurrency exchange Binance attributes its growing user base to rising inflation across the globe.

BTC

RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target

Related Posts

Freight Technologies Shoot Up After Chardan Capital’s Bullish Rating

Cincinnati Financial Q2 EPS $0.65 Misses $1.06 Estimate

Morgan Stanley Maintains Equal-Weight on Wynn Resorts, Raises Price Target to $95

Binance Says Worldwide Inflation Is Driving Crypto User Growth